Close Menu

Abbott

Labs are using specific protocols to mitigate the effects of biotin, a vitamin supplement that can interfere with test results.

Abbott received five separate clearances associated with its i-Stat Chem8+ cartridge running on the company's iStat 1 system.

The researchers are studying use of pharmacy testing to monitor hypertension and cholesterol as well as for detecting and managing various infectious diseases.

A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.

Abbott said the increase in diagnostics revenue was driven by adoption of the company's Alinity family of diagnostic instruments.

The company reported performance changes that led to the product recall and said it is pursuing eventual FDA clearance for the devices.

Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.

News items from the in vitro diagnostics industry for the week of Dec. 16, 2019.

The company's newest products and planned updates reveal a focus on operational efficiency and increasing automation for core lab management.  

 

The company said it plans to move all its immunoassays to a single vendor, representing an opportunity worth between $250 million and $400 million annually.

Pages